146 related articles for article (PubMed ID: 2076745)
21. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
22. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey.
Edwards DM; Marrari P; Efthymiopoulos C; Basileo G; Fraier D; Pianezzola E; Strolin-Benedetti M
Drug Metab Dispos; 1991; 19(5):938-45. PubMed ID: 1686240
[TBL] [Abstract][Full Text] [Related]
24. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.
Bressolle F; Jacquet JM; Galtier M; Jourdan J; Donadio D; Rossi JF
Cancer Chemother Pharmacol; 1992; 30(3):215-8. PubMed ID: 1628370
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of 4'-deoxy-4'-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin.
Formelli F; Carsana R; Pollini C
Cancer Res; 1987 Oct; 47(20):5401-6. PubMed ID: 3652044
[TBL] [Abstract][Full Text] [Related]
28. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; Charles BG
Aust Vet J; 2004 Dec; 82(12):769-72. PubMed ID: 15648940
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin and cisplatin excretion into human milk.
Egan PC; Costanza ME; Dodion P; Egorin MJ; Bachur NR
Cancer Treat Rep; 1985 Dec; 69(12):1387-89. PubMed ID: 4075315
[TBL] [Abstract][Full Text] [Related]
31. Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of weekly low dose doxorubicin.
Frenay M; Milano G; Renee N; Pons D; Khater R; François E; Thyss A; Namer M
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):191-5. PubMed ID: 2702975
[TBL] [Abstract][Full Text] [Related]
33. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.
Cummings J; Kerr DJ; Kaye SB
Cancer Chemother Pharmacol; 1987; 20(3):263-4. PubMed ID: 3677300
[TBL] [Abstract][Full Text] [Related]
34. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
[TBL] [Abstract][Full Text] [Related]
35. Bioanalysis of doxorubicin aglycone metabolites in human plasma samples-implications for doxorubicin drug monitoring.
Siebel C; Lanvers-Kaminsky C; Würthwein G; Hempel G; Boos J
Sci Rep; 2020 Oct; 10(1):18562. PubMed ID: 33122763
[TBL] [Abstract][Full Text] [Related]
36. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
[TBL] [Abstract][Full Text] [Related]
37. Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.
Boven E; de Jong J; Kuiper CM; Bast A; van der Vijgh WJ
Eur J Cancer; 1996 Jul; 32A(8):1382-7. PubMed ID: 8869103
[TBL] [Abstract][Full Text] [Related]
38. Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.
Sridhar KS; Krishan A; Samy TS; Sauerteig A; Wellham LL; McPhee G; Duncan RC; Anac SY; Ardalan B; Benedetto PW
Cancer Chemother Pharmacol; 1993; 31(6):423-30. PubMed ID: 8453681
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin clearance in the obese.
Rodvold KA; Rushing DA; Tewksbury DA
J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
[TBL] [Abstract][Full Text] [Related]
40. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.
Benjamin RS; Riggs CE; Bachur NR
Cancer Res; 1977 May; 37(5):1416-20. PubMed ID: 856462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]